Jasper hits record low as co halts asthma trial due to drug lot issue

Jasper Therapeutics

07/07/2025 16:54

Updates

** Drug developer Jasper Therapeutics' JSPR.O shares fall as much as 66.5% to all-time low of $2.27

** Stock set for its worst day in over 5 months, if losses hold

** Co
halts its asthma trial
 for experimental drug briquilimab due to a drug product lot issue that affected potency

** The same manufacturing problem impacted results in an early-stage study treating chronic spontaneous urticaria (CSU), a skin condition that causes red, itchy bumps

** Despite the issues, briquilimab achieved complete response at week 12 in CSU patients who received properly manufactured drug lots

** Jasper is investigating the issue and expects results in the coming weeks

** Despite Jasper's update on manufacturing issues delaying asthma and CSU trials to mid-2026, H.C. Wainwright analyst Emily Bodnar remains "encouraged on efficacy"

** As of last close, stock down 68.33% YTD

 (Reporting by Siddhi Mahatole and Kamal Choudhury)

 ((siddhi.mahatole@thomsonreuters.com))